Connect with us

Hi, what are you looking for?



Britain’s GSK joins race to develop China virus vaccine

GSK has said its work will complement the four projects already being funded through CEPI to develop a vaccine for the deadly virus/AFP

LONDON, United Kingdom, Feb 3 – The UK pharmaceuticals giant GlaxoSmithKline (GSK) said Monday it was joining a global race to develop a vaccine for a new strain of a deadly coronavirus that has killed more than 360 people.

The UK government also pledged £20 million ($26 million, 24 million euros) in funding for research at the Coalition for Epidemic Preparedness Innovations (CEPI) – a civil group formed at the World Economic Forum in Davos in 2017.

GSK said its work will complement the four projects already being funded through CEPI to develop a vaccine for the deadly China strain.

“Our (vaccine) adjuvant technology has previously been used successfully in the pandemic flu setting,” GSK Vaccine chief medical officer Thomas Breuer said in a statement.

“It enables using only small quantities of the vaccine antigen which allows the production of more doses of the vaccine — a crucial advantage in a pandemic.”

Adjuvant are agents that boost a body’s response to vaccine or other treatment.

The World Health Organization has declared a global virus emergency but refrained from calling the new epidemic a “pandemic”.

That term is reserved for disease that spread across multiple continents or worldwide.

CEPI was originally formed in response to the Ebola epidemic that killed more than 11,300 people of the 29,000 recorded cases in west Africa from 2013 to 2016.

“Our hope is that, with our partners, we can get an investigational vaccine from gene sequencing of the pathogen through to clinical testing in 16 week,” CEPI chief executive Richard Hatchett said.

Advertisement. Scroll to continue reading.

CEPI’s four other projects aimed at stamping out the new strain include a partnership between the US biotech company Moderna and the US National Institute of Allergy and Infectious Diseases.

GSK said it will initially be joining the work already being performed by the University of Queensland in Australia.

The other two projects involve the German biopharmaceutical company CureVac and the US-based Inovio pharmaceuticals firm.

UK Health Secretary Matt Hancock said the new government funding “will help our globally recognised vaccine development capabilities continue to develop new defences” against emerging threats.

Click to comment

More on Capital Business

Executive Lifestyle

NAIROBI, Kenya, Mar 12 – The country’s super wealthy individuals are increasing their holding of bonds, gold and cash, a new report by Knight...

Ask Kirubi

NAIROBI, Kenya, Mar 9 – Businessman and industrialist Dr. Chris Kirubi has urged members of the public to exercise extreme caution when making any...

Ask Kirubi

NAIROBI, Kenya, Mar 24 – Businessman and industrialist Dr. Chris Kirubi is set to own half of Centum Investment Company PLC, following a go-ahead...

Ask Kirubi

It is without a doubt that the COVID-19 pandemic has caught the whole world by surprise. Although its full impact is yet to be...


NAIROBI, Kenya, Mar 18 – Commercial Banks have been ordered to provide relief to borrowers on their personal loans, with loans eligible from March...


NAIROBI, Kenya, Jun17 – Kenya’s tea leaves manufacturer Kericho Gold, has been awarded the Superbrands Seal by Superbrands East Africa for their quality variety...


NAIROBI, Kenya, Apr 13 – As the local telecommunications industry gears up to roll out 5G networks in the country, the Communications Authority of...


NAIROBI, Kenya, Mar 22 – Airtel Kenya is offering free internet access for students in order to enable continued learning at home in the...